Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor. Dolsten’s ...
A combination shot including vaccines for both sicknesses failed to measure up in a Phase 3 trial, Pfizer said.
Pfizer faced a setback with its combo Covid-flu shot, which could allow Moderna and others to gain ground. Meanwhile, Epic’s ...
Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael Dolsten, told STAT he kept a chess set in his office that he got as a gift from a former CEO of the ...
Pfizer on Tuesday said Mikael Dolsten, chief scientific officer and president, Pfizer Research & Development, is leaving after more than 15 years with the drugmaker. Pfizer said it is launching ...
US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the ...
Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...
Pfizer on Tuesday Csaid hief Scientific Officer Mikael Dolsten, a key figure behind the development of its COVID-19 vaccine, will resign, after a more than 15-year career at the drugmaker.
Pfizer’s top scientist Mikael Dolsten is stepping down after leading the drugmaker’s research and development for the past 15 years, a period that includes Pfizer’s remarkable success ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer ...
Mikael Dolsten, Pfizer's outgoing chief scientific officer, said at a conference in March that the company hopes to launch its combination shot in 2025. It's unclear whether Friday's results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results